Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of ARO-APOC3 in adults with familial chylomicronemia syndrome
ISRCTN12904794Phase 3Completed
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Oct 2021
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, randomised trial of plozasiran in primary chylomicronemia (FCS) (4 arms), sponsored by Arrowhead Pharmaceuticals. Primary endpoint: Percent change from baseline in fasting triglycerides at Month 10. Started Oct 2021; status: completed.
02
Drugs
plozasiran
03
Conditions
primary chylomicronemia (FCS)
Beyond the preview
Go deeper on ISRCTN12904794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12904794.